EUVIMEDEUVIMED entdecken
Open Access

Serum N -Glycan Profiling Identifies Candidate Glycan Biomarkers for Early Detection and Prediction of Alzheimer’s Disease

Sherifdeen Onigbinde, Joy Solomon, Cristian D Gutierrez-Reyes, Oluwatosin Daramola, Mojibola Fowowe, Moyinoluwa Adeniyi, Kelly N DuBois, Kelly M Bakulski, Nicholas M Kanaan, David M Lubman iD, Yehia Mechref iD

Journal of Proteome Research · 2025

DOI: 10.1021/acs.jproteome.5c00018 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Proteome Research, 2025. Verfasst von Sherifdeen Onigbinde und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas 79409, United States. Hauptthemen laut MEDLINE: Alzheimer Disease, Polysaccharides, Cognitive Dysfunction. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIA NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer's disease (AD) is a neurodegenerative disorder marked by progressive cognitive decline, affecting millions worldwide. Early diagnosis and intervention are crucial yet challenging, particularly in distinguishing between Mild Cognitive Impairment (MCI) subtypes, which often precede AD. Recent studies have highlighted the significant role of glycosylation, specifically N-glycan alterations, in the pathogenesis of AD. This study utilizes advanced LC-MS/MS techniques to profile N-glycan changes between serum samples from participants with normal cognition denoted as (CTRL), nonamnestic MCI (naMCI), amnestic MCI (aMCI), and AD. The analysis identified 99 unique N-glycans and revealed distinct glycan expression patterns among the groups. Notably, sialylation was significantly upregulated in AD, while fucosylation was downregulated, suggesting their involvement in AD pathology. Additionally, the study examined the role of isomeric N-glycans, identifying several isomers that differentiate naMCI from aMCI and those that can monitor progression from aMCI to AD dementia. These findings emphasize the potential of N-glycans as biomarkers for early detection of AD and its precursors, offering new avenues for therapeutic intervention. The differential expression of specific N-glycans and their isomers could serve as valuable biomarkers for distinguishing MCI subtypes and predicting progression to AD dementia, thereby aiding in the development of targeted therapies aimed at mitigating cognitive decline in affected individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseasePolysaccharidesCognitive DysfunctionHumansBiomarkersAgedMaleFemaleEarly DiagnosisTandem Mass SpectrometryChromatography, LiquidGlycosylationAged, 80 and over

Stichwörter der Autor:innen

Alzheimer’s diseaseLC-MS/MSN-glycansbiomarkersisomersmild cognitive impairments

Substanzen

PolysaccharidesBiomarkers

Autor:innen und Institutionen

  • Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas 79409, United States.
  • Department of Translational Science and Molecular Medicine, College of Human Medicine, Michigan State University, Grand Rapids, Michigan 49503, United States.
  • Michigan Alzheimer's Disease Research Center, University of Michigan, Ann Arbor, Michigan 48103, United States.
  • Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan 48103, United States.
  • Department of Surgery, The University of Michigan, Ann Arbor, Michigan 48109, United States.

ORCID-Profile: David M Lubman, Yehia Mechref

Förderung

  • NIGMS NIH HHS
  • NIA NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • Welch Foundation
  • National Institute on Aging
  • CH Foundation
  • National Institute of General Medical Sciences

Zitieren

APA

Onigbinde, S., Solomon, J., Gutierrez-Reyes, C. D., Daramola, O., Fowowe, M., Adeniyi, M., DuBois, K. N., Bakulski, K. M., Kanaan, N. M., Lubman, D. M., & Mechref, Y. (2025). Serum N -Glycan Profiling Identifies Candidate Glycan Biomarkers for Early Detection and Prediction of Alzheimer’s Disease. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.5c00018

Vancouver

Onigbinde S, Solomon J, Gutierrez-Reyes CD, Daramola O, Fowowe M, Adeniyi M, et al. Serum N -Glycan Profiling Identifies Candidate Glycan Biomarkers for Early Detection and Prediction of Alzheimer’s Disease. Journal of Proteome Research. 2025. doi:10.1021/acs.jproteome.5c00018

BibTeX
@article{Onigbinde2025,
  author = {Onigbinde, Sherifdeen and Solomon, Joy and Gutierrez-Reyes, Cristian D and Daramola, Oluwatosin and Fowowe, Mojibola and Adeniyi, Moyinoluwa and DuBois, Kelly N and Bakulski, Kelly M and Kanaan, Nicholas M and Lubman, David M and Mechref, Yehia},
  title = {Serum N -Glycan Profiling Identifies Candidate Glycan Biomarkers for Early Detection and Prediction of Alzheimer’s Disease},
  journal = {Journal of Proteome Research},
  year = {2025},
  doi = {10.1021/acs.jproteome.5c00018}
}
Kostenlos starten →